Establishment Labs Holdings ^{Priced, Nasdaq: ESTA}

We are a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market. Our line of silicone gel-filled breast implants, branded as Motiva Implants, is the centerpiece of our MotivaImagine medical technology platform. Self-collected and as well as third-party data indicates that Motiva Implants show low rates of adverse events (including rupture, capsular contracture, etc.) that we believe compare favorably with those of our competitors. We believe the proprietary technologies that differentiate our Motiva Implants enable improved safety and aesthetic outcomes and have helped drive our revenue growth. Our MotivaImagine platform enables surgical techniques that we promote as Motiva branded surgeries. We have developed other complementary products and services on our MotivaImagine platform, which are aimed at further enhancing patient outcomes. We began selling Motiva Implants outside the United States in October 2010; since then, we have introduced four generations of Motiva Implants, and Motiva Implants are now sold in over 60 countries. We received approval of an investigational device exemption (IDE) from the FDA in March 2018 to initiate our Motiva Implant clinical trial in the US, and we anticipate completing enrollment in early 2019.